Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Hormone Replacement Therapy in Menopause — pipeline assessment and market forecasts to 2017

Summary

The report is an essential source of information and analysis on the global menopause hormone therapy market. The report identifies the key trends shaping and driving the global menopause hormone therapy market.

The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global menopause hormone therapy sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates the global hormone therapy (HT) market was worth $2.4 billion in 2009, indicating a Compound Annual Growth Rate (CAGR) of -5.9% between 2001 and 2009. This decline in the market is mainly attributed to poor patient compliance as a result of the serious safety concerns associated with hormones.

By 2017, the market is forecast to be worth $2.8 billion, with a CAGR of 2.2% between 2009 and 2017. The market is restrained by factors such as the poor acceptance of hormone therapies in patients and physicians. Increased interest in low-dose and ultra-low dose hormone therapies are expected to lead to marginal growth of the HT market.

Scope

The report provides information on the key drivers and challenges in the menopause hormone therapy market. Its scope includes:

• Annualized global menopause hormone therapy market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. These drugs are estrogens or progestins (including combination therapies and low-dose therapies), non-hormonal products such as serum estrogen receptor modulators, serotonin reuptake inhibitors, estrogen receptor alpha agonists, among others.
• Analysis of the current and future competition in the global menopause hormone therapy market. The key market players covered are Pfizer, Merck & Co, Amgen, BioSante Pharmaceuticals, Noven Pharmaceuticals, Bionovo, QuatRx Pharmaceuticals and Depomed.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hormone replacement therapy market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global menopause hormone therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global menopause hormone therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global menopause hormone therapy market landscape? — Identify, understand and capitalize.

Buy now >>
(managed by GlobalData)

To top